Vividion Therapeutics, Inc.

Bayer has asked investors for patience as the conglomerate works its way through various challenges across its pharmaceuticals, crop science and consumer health businesses, and in 2024 pharma showed t

In the maturing landscape of cell therapy, Artiva Biotherapeutics stands out for its unique approach: using un-engineered natural killer (NK) cells for oncologic and immune indications. Under the lead

Founded eight years ago, Bayer subsidiary BlueRock Therapeutics is now putting the final touches to the late-stage program for bemdaneprocel, its closely watched investigational cell therapy for Parki

Nearly three and a half years after being bought by Bayer, Vividion Therapeutics has itself hit the acquisition trial to buy the US precision oncology platform company Tavros Therapeutics. Vividion sa